Literature DB >> 25332978

Plasma tumor DNA: on your markers, get set, go!

Hong Yuen Wong1, Ben Ho Park1.   

Abstract

Metastatic breast cancer is incurable, yet highly treatable with endocrine, HER2 directed and chemotherapies improving survival for many patients. Successful treatment depends on the ability to monitor disease burden and response to therapies. Recently, a proof of principle study has shown that plasma tumor DNA (ptDNA) can be used as a reliable breast cancer biomarker in metastatic disease, due to its sensitivity and wide dynamic range. ptDNA more accurately reflects changes in response to therapies, and absolute levels of ptDNA demonstrate prognostic significance. Thus, ptDNA as a liquid biopsy shows great promise in the clinical management of metastatic breast cancer though further technical challenges and larger confirmatory studies are needed.

Entities:  

Keywords:  Plasma tumor DNA (ptDNA); circulating tumor DNA (ctDNA); metastatic breast cancer; plasma biomarker

Year:  2014        PMID： 25332978      PMCID： PMC4200658          DOI： 10.3978/j.issn.2305-5839.2013.06.07

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  19 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

Authors:  Tim Forshew; Muhammed Murtaza; Christine Parkinson; Davina Gale; Dana W Y Tsui; Fiona Kaper; Sarah-Jane Dawson; Anna M Piskorz; Mercedes Jimenez-Linan; David Bentley; James Hadfield; Andrew P May; Carlos Caldas; James D Brenton; Nitzan Rosenfeld
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

Review 3.  Circulating tumour-derived predictive biomarkers in oncology.

Authors:  Darren R Hodgson; Robert Wellings; Maria C M Orr; Rose McCormack; Michael Malone; Ruth E Board; Mireille V Cantarini
Journal:  Drug Discov Today       Date:  2010-01-04       Impact factor: 7.851

4.  Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Authors:  Frank Diehl; Meng Li; Devin Dressman; Yiping He; Dong Shen; Steve Szabo; Luis A Diaz; Steven N Goodman; Kerstin A David; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-28       Impact factor: 11.205

5.  Circulating Tumor Nucleic Acids: Perspective in Breast Cancer.

Authors:  Ida Casciano; Angela Di Vinci; Barbara Banelli; Claudio Brigati; Alessandra Forlani; Giorgio Allemanni; Massimo Romani
Journal:  Breast Care (Basel)       Date:  2010-04-23       Impact factor: 2.860

6.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

7.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA.

Authors:  Carlo Rago; David L Huso; Frank Diehl; Baktiar Karim; Guosheng Liu; Nickolas Papadopoulos; Yardena Samuels; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Luis A Diaz
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls.

Authors:  M B Giacona; G C Ruben; K A Iczkowski; T B Roos; D M Porter; G D Sorenson
Journal:  Pancreas       Date:  1998-07       Impact factor: 3.327

9.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

10.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962
View more
  2 in total

1.  Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.

Authors:  Yu-Hsiang Chen; Bradley A Hancock; Jeffrey P Solzak; Dumitru Brinza; Charles Scafe; Kathy D Miller; Milan Radovich
Journal:  NPJ Breast Cancer       Date:  2017-07-03

Review 2.  Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.

Authors:  Benoit Busser; Julien Lupo; Lucie Sancey; Stéphane Mouret; Patrice Faure; Joel Plumas; Laurence Chaperot; Marie Thérèse Leccia; Jean Luc Coll; Amandine Hurbin; Pierre Hainaut; Julie Charles
Journal:  Biomed Res Int       Date:  2017-04-06       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.